TABLE 3.
Laboratory tests before and after the administration of tocilizumab in the improvement group and the death group.
| Improvement group (N = 27) | p-value | Death group (N = 12) | p-value | |||
| Before TCZ | After TCZ | Before TCZ | After TCZ | |||
| WBC (× 109/L) | 6.3 (4.1–8.8) | 4.8 (3.9–6.2) | 0.0746 | 8.55 (4.9–12.3) | 9.8 (4.6–14.0) | 0.8311 |
| PCT (ng/ml) | 0.07 (0.05–0.11) | 0.05 (0.04–0.06) | 0.3088 | 0.79 (0.16–1.9) | 1.75 (0.44–5.5) | 0.3750 |
| LDH (U/L) | 264.5 (192–310) | 219 (193–234) | 0.0096 | 499 (412–614.5) | 537 (488.5–626.5) | 0.8750 |
| Lymphocyte count (× 109/L) | 0.71 (0.44–0.93) | 1.3 (1.1–1.5) | <0.0001 | 0.65 (0.49–0.89) | 0.265 (0.12–0.81) | 0.0269 |
| Lymphocyte percentage (%) | 14.6 (6.8–20.5) | 24.6 (15.9–29.9) | <0.0001 | 6.15 (3.00–7.05) | 7.05 (3.4–11.4) | 1.0000 |
| Hs-CRP (mg/L) | 24.4 (9.07–87.2) | 1.42 (0.56–5.06) | <0.0001 | 54.7 (23.9–112.2) | 20.67 (9.5–125.9) | 0.7910 |
| IL-6 (pg/ml) | 53.2 (33.8–91.4) | 110.5 (16.0–3327.1) | 0.0132 | 140.4 (69.9–316.5) | 1216 (584.9–3504.0) | 0.0059 |
| D-dimer (mg/L) | 2.7 (1.0–5.1) | 1.2 (0.73–2.7) | <0.0001 | 3.51 (1.6–6.5) | 10.17 (2.8–21.9) | 0.0371 |
| Oxygen saturation% | 92 (88–95) | 98 (97–99) | <0.0001 | 86.5 (84.5–92.5) | 85 (80–92.5) | 0.6240 |
CHD, coronary artery heart disease; COPD, chronic obstructive pulmonary disease; hs-CRP, high-sensitive C-reactive protein; IL-6, interleukin-6; LDH, lactate dehydrogenase; PCT, procalcitonin; TCZ, tocilizumab; WBC, white blood cell. There was statistical difference in bold type.